Contraception News and Research RSS Feed - Contraception News and Research

Federal appellate court hears arguments challenging health law's birth control mandate

The Seventh U.S. Circuit Court of Appeals in Chicago is the first federal appellate court to hear arguments in cases challenging the mandate that took effect last August. With dozens of similar lawsuits pending, many say the issue seems likely to land before the Supreme Court. The case brought by Hobby Lobby Inc. is considered the most prominent of these efforts. [More]

Market pressures may keep premiums low as health law kicks in

USA Today reports this optimisitic view is offered by some industry analysts and health insurance officials. Meanwhile, Politico does a status check on the legal challenges to the health law's birth control mandate. News reports also track the latest regarding the Internal Revenue Service controversy and the overhaul. [More]
First Edition: May 23, 2013

First Edition: May 23, 2013

Today's headlines include various status updates about state activity regarding the health law's online insurance marketplaces. [More]
Bayer HealthCare to present new data on oncology portfolio at ASCO meeting

Bayer HealthCare to present new data on oncology portfolio at ASCO meeting

Bayer HealthCare announced today that new data on the oncology portfolio, including Nexavar (sorafenib) tablets, Stivarga (regorafenib) tablets and the recently U.S. Food and Drug Administration approved product Xofigo (radium Ra 223 dichloride) injection will be presented at the 49th Annual Meeting of the American Society of Clinical Oncology, May 31 – June 4, in Chicago, IL (USA). [More]
Bayer HealthCare: Patient enrollment underway in Phase III trial of Stivarga tablets for treatment of HCC

Bayer HealthCare: Patient enrollment underway in Phase III trial of Stivarga tablets for treatment of HCC

Bayer HealthCare announced today that patient enrollment is underway for RESORCE (Regorafenib after Sorafenib in Patients with Hepatocellular Carcinoma), an international Phase III trial to evaluate the efficacy and safety of Stivarga (regorafenib) tablets for the treatment of patients with hepatocellular carcinoma who have progressed on Nexavar (sorafenib) tablets, an anticancer medicine for the treatment of patients with unresectable HCC. [More]

Obama administration asks appeals court to delay judge's order on emergency contraceptive

The federal government's legal fight over the availability of emergency contraception is heating up at the next level in the courts. [More]

First Edition: May 14, 2013

Today's headlines include reports about an Obama administration plan to delay Medicaid DSH payment reductions. [More]

Catholic-secular hospital mergers further complicate crowded abortion-rights battlefield

Mergers between Catholic and secular hospitals could mean wider restriction of abortion, even as lawmakers in many states consider tighter regulation or bans on the procedure. [More]
First Edition: May 13, 2013

First Edition: May 13, 2013

Today's headlines include reports that Health and Human Services Secretary Kathleen Sebelius has been seeking out funds from private sources to support efforts to publicize the health law. [More]
RA, anti-TNF drugs and abortion rates: an interview with Dr. Evelyne Vinet and Dr. Sasha Bernatsky, McGill University

RA, anti-TNF drugs and abortion rates: an interview with Dr. Evelyne Vinet and Dr. Sasha Bernatsky, McGill University

Prednisone and non-steroidal anti-inflammatory drugs (NSAIDs) can be used for symptom control, but to prevent joint damage, we use disease-modifying anti-rheumatic drugs (DMARDs) including the cornerstone, methotrexate. [More]

Most women alter bleeding cycles, find researchers

A surprisingly large number of women 18 or older choose to delay or skip monthly menstruation by deviating from the instructions of birth-control pills and other hormonal contraceptives, a team of University of Oregon researchers and others found in a study of female students at the university. [More]

Federal judge criticizes FDA regarding Plan B contraception decision

Judge Edward R. Korman said the Food and Drug Administration's efforts to delay his ruling regarding the so-called morning-after pill was "nonsense" and would hurt poor and minority women. [More]

Using copper IUD or coil does not exacerbate period pain, reveals study

Using a copper intrauterine device (IUD), or coil, does not exacerbate period pain, reveals a study where researchers from the Sahlgrenska Academy, University of Gothenburg, Sweden, followed 2,100 women for 30 years. [More]

First Edition: May 8, 2013

Today's headlines include reports about government data showing the wide variation in what hospitals charge Medicare patients for common inpatient procedures. [More]
Viewpoints: Medicaid's effect on health debated; Young adults central to lowering anxiety about online marketplaces

Viewpoints: Medicaid's effect on health debated; Young adults central to lowering anxiety about online marketplaces

A study comparing low-income people in Oregon who received access to Medicaid over the past two years with those who did not, found that those on Medicaid visited doctors and hospitals more often, suffered less from depression and were more financially secure. [More]
Viewpoints: Liberals refuse to acknowledge evidence of Oregon Medicaid study; Politics is roiling science in emergency contraception decisions

Viewpoints: Liberals refuse to acknowledge evidence of Oregon Medicaid study; Politics is roiling science in emergency contraception decisions

A familiar critique of liberal governance is that the results always matter less than its grand social ambitions. The latest evidence of this truth comes in the reaction to disappointing new findings from one of the most important public-policy experiments since the 1970s. A team of varsity health economists, mostly at Harvard and MIT, is studying the relationship between health outcomes and health insurance delivered by Medicaid (5/2). [More]
FDA approves sNDA for SUSTIVA for treatment of HIV-1 infected pediatric patients

FDA approves sNDA for SUSTIVA for treatment of HIV-1 infected pediatric patients

Bristol-Myers Squibb Company today announced that the U.S. Food and Drug Administration has approved a supplemental new drug application for SUSTIVA (efavirenz), including dosing recommendations for HIV-1 infected pediatric patients three months to three years old and weighing at least 3.5 kg. [More]

Obama 'comfortable' with morning-after pill sales at 15

President Barack Obama said he is "very comfortable" with the Food and Drug Administration rule announced this week to make the so-called morning after pill available without a prescription to women and girls who are at least 15 -- younger than the current limit of 17. [More]

Obama administration plans appeal of 'Plan B' ruling

The Obama administration signals that it will challenge a federal judge's order that would make an emergency contraception drug available over-the-counter to women of all ages. The move comes a day after the FDA said the contraception should be available in that way to anyone older than 15. [More]

FDA OKs over-the-counter 'Plan B' contraception for women and girls older than age 15

The move, regulators said, was made independent of a recent federal district judge's ruling that called for the emergency contraceptive to be made available over-the-counter to women of all ages without restriction. [More]